Moderna Cancer Vaccine Trial Success
6 articles from 4 countries
Moderna's personalized mRNA cancer vaccine achieved positive results in a Phase 3 trial for melanoma, leading to a significant surge in its stock price. The success follows the company's earlier prominence as a COVID-19 vaccine provider.
Moderna's Personalized Cancer Vaccine Succeeds in Phase 3 Trial; Domestic Tech Aims for 2027 Clinical Challenge | Dong-A Ilbo (KR) | Korean News | Health & Science | Positive | News | Unclear Sourcing | Announced
- Moderna's personalized mRNA cancer vaccine has shown positive results in a Phase 3 clinical trial for melanoma. - South Korean company Neogene Logic is preparing to apply for clinical trial approval in 2027 using its AI-driven neoantigen technology. - This development signals progress in the field of personalized cancer immunotherapy, with both global and domestic players advancing their researc…
Merck and Moderna announce positive results for experimental mRNA skin cancer vaccine
- Merck and Moderna announced positive Phase 3 trial results for their experimental mRNA skin cancer vaccine. - The personalized therapy, combined with Merck's Keytruda immunotherapy, significantly im…
Medicinal stock soars after new cancer vaccine data
- Moderna's stock surged 85% after announcing positive Phase 3 trial results for a personalized cancer vaccine. - The mRNA-based vaccine, developed with Merck, showed it can reduce the risk of melanom…
Promising Results for Experimental Cancer Vaccine in Melanoma Trial
- An experimental personalized cancer vaccine developed by Moderna and Merck has shown promising results in a Phase 3 clinical trial for melanoma. - The mRNA-based vaccine, used in combination with Me…
Moderna Cancer Vaccine Trial Success Fuels 177% Stock Surge
- Moderna announced its personalized mRNA cancer vaccine, developed with Merck, met its primary endpoint in a Phase 3 trial for high-risk melanoma patients. - The vaccine, known as intisemera autogene…
Moderna's stock doubles on cancer vaccine success after COVID-19 hero status fades
- Moderna, once hailed as a COVID-19 hero, has seen its stock price double following success in its cancer vaccine trials. - The company's stock had previously fallen significantly after its prominent…
